LTS LOHMANN Therapie-Systeme AG (LTS) and Grand River Aseptic Manufacturing (GRAM) entered a strategic alliance focused on sterile fill finish for containers used in LTS’ Sorrel wearable injector devices. This collaboration aims to offer pharmaceutical companies a comprehensive solution for both the development and manufacturing of wearable injectors specifically designed for the delivery of biologics. With an integrated approach from concept to completion, the goal is to facilitate faster market access and streamlined production processes.
 
Sorrel is a next-gen on-body delivery system for large-volume and/or viscous drug formulations designed for patient convenience and pharmaceutical efficiency. Its patented technology supports multiple drugs and indications for at-home delivery. Sorrel is designed to help pharmaceutical partners reduce development risks like safety, efficacy, cost, and time-to-market.
 
GRAM, an aseptic fill and finish CDMO, particularly for injectable biologics, offers capabilities that span sterile production, regulatory guidance, and product development support with scalable manufacturing services. GRAM handles the complex requirements of sterile fill finish for specialized containers such as cartridges and wearable injectors.
 
“We see a very synergistic alliance between LTS and GRAM, creating a mutually beneficial collaboration that particularly supports our customers’ journey from molecule to market,” said Dr. Andrei Yosef, President and General Manager of LTS Device Technologies. “The combination of GRAM’s fill-finish expertise with LTS’s proprietary Sorrel™ drug delivery technology will deliver a streamlined solution that meets the unique needs of our customers.”
 
“We are excited to embark on this collaboration with LTS, as on-body wearable injectors are crucial for advancing patient care. This collaboration leverages our dedicated efforts, combining GRAM’s specialized aseptic manufacturing capabilities with LTS’s innovative device technology. Together, we are not only advancing the technology but also enhancing patient care by making sophisticated treatments more accessible and easier to use,” said Dave Powell, Vice President of Business Development at GRAM.